Skip to main content

Articles

Page 5 of 5

  1. Cancer survivors experience on average a 20% reduction in peak exercise capacity (VO2 peak) post-cancer treatment. Intermuscular fat (IMF) is a strong predictor of reduced exercise capacity in heart failure (HF) ...

    Authors: Kerryn W. Reding, Peter Brubaker, Ralph D’Agostino Jr, Dalane W. Kitzman, Barbara Nicklas, Dale Langford, Michael Grodesky and W. Gregory Hundley
    Citation: Cardio-Oncology 2019 5:3
    Content type: Short communication Published on:

  2. Anthracycline chemotherapy is an effective and widely used treatment for solid tumors and hematological malignancies regardless of its known cardiotoxicity. The mechanisms of the cardiotoxicity are not fully u...

    Authors: Amanda J. Favreau-Lessard, Hagen Blaszyk, Michael A. Jones, Douglas B. Sawyer and Ilka M. Pinz
    Citation: Cardio-Oncology 2019 5:2
    Content type: Research Published on:

  3. Cardiotoxicity associated with anthracycline-based chemotherapies has limited their use in patients with preexisting cardiomyopathy or heart failure. Dexrazoxane protects against the cardiotoxic effects of ant...

    Authors: Sarju Ganatra, Anju Nohria, Sachin Shah, John D. Groarke, Ajay Sharma, David Venesy, Richard Patten, Krishna Gunturu, Corrine Zarwan, Tomas G. Neilan, Ana Barac, Salim S. Hayek, Sourbha Dani, Shantanu Solanki, Syed Saad Mahmood and Steven E. Lipshultz
    Citation: Cardio-Oncology 2019 5:1
    Content type: Research Published on:

  4. Emerging evidence suggests potential arterial damage with the use of anthracycline-based chemotherapeutic regimens. We determined arterial function at rest and during exercise in anthracycline-treated adult su...

    Authors: Vivian Wing-yi Li, Anthony Pak-yin Liu, Karin Kar-Huen Ho, Jeffrey Ping-Wa Yau, Daniel Ka-leung Cheuk and Yiu-fai Cheung
    Citation: Cardio-Oncology 2018 4:9
    Content type: Research Published on:

  5. Cancer survivors treated with thoracic ionizing radiation are at higher risk of premature death due to myocardial ischemia. No therapy is currently available to prevent or mitigate these effects. We tested the...

    Authors: Umesh C. Sharma, Swati D. Sonkawade, Andrew Baird, Min Chen, Shirley Xu, Sandra Sexton, Anurag K. Singh, Adrienne Groman, Steven G. Turowski, Joseph A. Spernyak, Supriya D. Mahajan and Saraswati Pokharel
    Citation: Cardio-Oncology 2018 4:8
    Content type: Research Published on:

  6. Cardiotoxic effects of anthracycline therapy are a major cause of morbidity for childhood cancer survivors. The aim of this retrospective evaluation is to assess the efficacy of Tissue Doppler Imaging in the e...

    Authors: Francesco Venturelli, Riccardo Masetti, Marianna Fabi, Roberto Rondelli, Anna Martoni, Arcangelo Prete, Marco Bonvicini and Andrea Pession
    Citation: Cardio-Oncology 2018 4:6
    Content type: Research Published on:

  7. Doxorubicin chemotherapy is used across a range of adult and pediatric malignancies. Cardiac toxicity is common, and dysfunction develops over time in many patients. Biomarkers used for predicting late cardiac...

    Authors: Andrew Poklepovic, Yuesheng Qu, Molly Dickinson, Michael C. Kontos, Maciej Kmieciak, Elizabeth Schultz, Dipankar Bandopadhyay, Xiaoyan Deng and Rakesh C. Kukreja
    Citation: Cardio-Oncology 2018 4:7
    Content type: Research Published on:

  9. Anthracycline induced cardiomyopathy is a major cause of mortality and morbidity among pediatric cancer survivors. It has been postulated that oxidative stress induction and inflammation may play a role in the...

    Authors: Olga H. Toro-Salazar, Ji Hyun Lee, Kia N. Zellars, Paige E. Perreault, Kathryn C. Mason, Zhu Wang, Kan N. Hor, Eileen Gillan, Caroline J. Zeiss, Daniel M. Gatti, Brooke T. Davey, Shelby Kutty, Bruce T. Liang and Francis G. Spinale
    Citation: Cardio-Oncology 2018 4:4
    Content type: Research Published on:

  10. Approximately 2–3% of patients undergoing advanced heart failure therapies such as left ventricular assist devices (LVAD) and orthotropic heart transplantation (OHT) have chemotherapy-related cardiomyopathy, a...

    Authors: Raquel Araujo-Gutierrez, Sergio H. Ibarra-Cortez, Jerry D. Estep, Arvind Bhimaraj, Ashrith Guha, Imad Hussain, Myung H. Park, Guillermo Torre-Amione and Barry H. Trachtenberg
    Citation: Cardio-Oncology 2018 4:3
    Content type: Research Published on:

  11. Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed mu...

    Authors: Eric H. Yang, Cynthia Courtney, Vinisha Garg, Michael G. Fradley and Gary J. Schiller
    Citation: Cardio-Oncology 2018 4:2
    Content type: Short Communication Published on:

  12. Studies of cancer survivors treated with older radiotherapy (RT) techniques (pre-1990s) strongly suggest that ionizing radiation to the chest increases the risk of coronary heart disease (CHD). Our goal was to...

    Authors: Michael Jacob Adams, Susan G. Fisher, Steven E. Lipshultz, Roy E. Shore, Louis S. Constine, Marilyn Stovall, Ann Dozier, Kelly Thevenet-Morrison, Robert Block, Ronald G. Schwartz and Thomas A. Pearson
    Citation: Cardio-Oncology 2018 4:1
    Content type: Research Published on:

  13. Patients with cancer treatment-related cardiotoxicity, which may manifest as heart failure (HF), can present with dyspnea. Nurses frequently assess, triage and offer self-care strategies to patients experienci...

    Authors: F. Kelly, S. L. Carroll, M. Carley, S. Dent, R. Shorr, J. Hu, R. Morash and D. Stacey
    Citation: Cardio-Oncology 2017 3:7
    Content type: Research Published on:

  14. Cardiotoxicity from anticancer therapy affects heart function and structure. Cardiotoxicity can also lead to accelerated development of chronic diseases, especially in the presence of risk factors.

    Authors: Robyn A. Clark, Tania S. Marin, Narelle M. Berry, John J. Atherton, Jonathon W. Foote and Bogda Koczwara
    Citation: Cardio-Oncology 2017 3:6
    Content type: Research Published on:

  15. Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC) has been associated with hypertension (HTN), cardiomyopathy, and cardiac dys...

    Authors: Daniel Pinkhas, Thai Ho and Sakima Smith
    Citation: Cardio-Oncology 2017 3:5
    Content type: Research Published on:

  16. Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. Howe...

    Authors: John H. Chen, Daniel J. Lenihan, Sharon E. Phillips, Shelton L. Harrell and Robert F. Cornell
    Citation: Cardio-Oncology 2017 3:4
    Content type: Research Published on:

  18. Atrial fibrillation (AF) is frequently observed in patients being treated for cancer and can lead to increased morbidity and mortality in this population. With the use of newer, targeted cancer therapies, seve...

    Authors: Aarti Asnani, Anastasia Manning, Moussa Mansour, Jeremy Ruskin, Ephraim P. Hochberg and Leon M. Ptaszek
    Citation: Cardio-Oncology 2017 3:2
    Content type: Review Published on:

  19. Sinus bradycardia is frequently observed in patients treated with crizotinib, a receptor tyrosine kinase inhibitor used for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung canc...

    Authors: Zhushan Zhang, Tai-Qin Huang, Igor Nepliouev, Hengtao Zhang, Adam S. Barnett, Paul B. Rosenberg, Sai-Hong I. Ou and Jonathan A. Stiber
    Citation: Cardio-Oncology 2017 3:1
    Content type: Research Published on:

  20. Due to aging of the population and cardiotoxic cancer treatment, there is an increasing group of patients with cancer and co-morbid cardiovascular disease (CVD). In order to find a balance between the risk of ...

    Authors: Dounya Schoormans, Susanne S. Pedersen, Susanne Dalton, Nina Rottmann and Lonneke van de Poll-Franse
    Citation: Cardio-Oncology 2016 2:9
    Content type: Short communication Published on:

  21. The treatment of Acute Myeloid Leukemia (AML) leads to several functional limitations. Especially cardiac burden following cardiotoxic chemotherapy, which limits exercise and competitive sport in the long-term...

    Authors: Pia von Korn, Manfred Vogt, Renate Oberhoffer, Peter Ewert and Jan Müller
    Citation: Cardio-Oncology 2016 2:8
    Content type: Short communication Published on:

  22. The presence and burden of coronary artery calcium (CAC) is a strong predictor of cardiovascular events. In an effort to gain insight into the utility of CAC for coronary artery disease (CAD) screening in canc...

    Authors: Alison M. Brann, Charlotte J. Bai, John F. Hibbeln, Kim A. Williams and Tochi M. Okwuosa
    Citation: Cardio-Oncology 2016 2:7
    Content type: Research Published on:

  23. Electrocardiographic changes may manifest in patients with pericardial effusions. PR segment changes are frequently overlooked, but when present, can provide diagnostic significance. The diagnostic value of PR...

    Authors: M. Ahluwalia, R. O’Quinn, B. Ky, D. Callans, J. Kucharczuk and J. R. Carver
    Citation: Cardio-Oncology 2016 2:6
    Content type: Research Published on:

  24. The diagnosis and management of cardiovascular complications have become a clinical concern for oncologists, cardiologists, surgeons, interventional radiologists, radiation therapy physicians, internists, nurs...

    Authors: Sergio Barros-Gomes, Joerg Herrmann, Sharon L. Mulvagh, Amir Lerman, Grace Lin and Hector R. Villarraga
    Citation: Cardio-Oncology 2016 2:5
    Content type: Review Published on:

  25. Doxorubicin (DOX) is a very effective anticancer medication that is commonly used to treat hematological malignancies and solid tumors. Nevertheless, DOX is known to have cardiotoxic effects that may lead to c...

    Authors: Beshay N. Zordoky, M. Judith Radin, Lois Heller, Anthony Tobias, Ilze Matise, Fred S. Apple, Sylvia A. McCune and Leslie C. Sharkey
    Citation: Cardio-Oncology 2016 2:4
    Content type: Research Published on:

  27. The cardiotoxicity of doxorubicin is becoming an interdisciplinary point of interest given a growing population of cancer survivors. The complex and not completely understood pathogenesis of this complication ...

    Authors: Antonella De Angelis, Konrad Urbanek, Donato Cappetta, Elena Piegari, Loreta Pia Ciuffreda, Alessia Rivellino, Rosa Russo, Grazia Esposito, Francesco Rossi and Liberato Berrino
    Citation: Cardio-Oncology 2016 2:2
    Content type: Review Published on:

  29. New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular ...

    Authors: Yishay Wasserstrum, Ran Kornowski, Pia Raanani, Avi Leader, Oren Pasvolsky and Zaza Iakobishvili
    Citation: Cardio-Oncology 2015 1:6
    Content type: Review Published on:

  30. Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improvi...

    Authors: Oren Pasvolsky, Avi Leader, Zaza Iakobishvili, Yishay Wasserstrum, Ran Kornowski and Pia Raanani
    Citation: Cardio-Oncology 2015 1:5
    Content type: Review Published on:

  32. Afatinib is an oral irreversible ErbB family blocker that targets epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and HER4 (ErbB4) and is approved for the ...

    Authors: Michael S. Ewer, Kalpesh Patel, Dennis O’Brien and Robert M. Lorence
    Citation: Cardio-Oncology 2015 1:3
    Content type: Review Published on:

  34. Subacute cardiotoxicity, consisting of acute myocyte damage and associated left ventricular dysfunction, occurs early during anthracycline therapy. We investigated the impact of myocardial dysfunction, defined...

    Authors: Olga H. Toro-Salazar, Eileen Gillan, Joanna Ferranti, Andrea Orsey, Karen Rubin, Shailendra Upadhyay, Wojciech Mazur and Kan N. Hor
    Citation: Cardio-Oncology 2015 1:1
    Content type: Research Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 3.2
    5-year Journal Impact Factor: N/A
    Source Normalized Impact per Paper (SNIP): 0.822
    SCImago Journal Rank (SJR): 0.958

    Speed 2023
    Submission to first editorial decision (median days): 16
    Submission to acceptance (median days): 127

    Usage 2023
    Downloads: 302,427
    Altmetric mentions: 315

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Cardio-Oncology

ISSN: 2057-3804

Contact us